Rapport Therapeutics (RAPP) Projected to Announce Earnings on Thursday

Rapport Therapeutics (NASDAQ:RAPP) is projected to issue its Q3 2026 results before the market opens on Thursday, November 5th. Analysts expect the company to post earnings of ($1.20) per share for the quarter. Parties can find conference call details on the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Friday, November 6, 2026 at 9:30 AM ET.

Rapport Therapeutics (NASDAQ:RAPP) last issued its quarterly earnings results on Wednesday, August 5th. The company reported ($1.19) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.12) by ($0.07). On average, analysts expect Rapport Therapeutics to post ($4.08) EPS for the current fiscal year and ($5.05) EPS for the next fiscal year.

Rapport Therapeutics Stock Down 18.3%

RAPP stock opened at $22.50 on Thursday. Rapport Therapeutics has a 52-week low of $22.06 and a 52-week high of $52.93. The stock’s fifty day simple moving average is $37.66 and its 200-day simple moving average is $35.61. The stock has a market capitalization of $1.08 billion, a price-to-earnings ratio of -7.40 and a beta of 1.22.

Insider Buying and Selling at Rapport Therapeutics

In other Rapport Therapeutics news, Director Wendy B. Young acquired 3,789 shares of the company’s stock in a transaction dated Thursday, October 22nd. The stock was bought at an average price of $26.39 per share, with a total value of $99,991.71. Following the completion of the transaction, the director directly owned 13,289 shares of the company’s stock, valued at approximately $350,696.71. The trade was a 39.88% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director John Maraganore bought 9,411 shares of the business’s stock in a transaction dated Thursday, October 22nd. The stock was acquired at an average cost of $26.45 per share, for a total transaction of $248,920.95. Following the purchase, the director owned 9,411 shares in the company, valued at approximately $248,920.95. This trade represents a ∞ increase in their position. The SEC filing for this purchase provides additional information. In the last ninety days, insiders have bought 61,694 shares of company stock worth $1,664,818 and have sold 97,976 shares worth $4,391,729. Company insiders own 12.48% of the company’s stock.

Analysts Set New Price Targets

Several research firms recently commented on RAPP. BTIG Research upped their target price on Rapport Therapeutics from $75.00 to $89.00 and gave the company a “buy” rating in a research note on Tuesday, October 20th. HC Wainwright reiterated a “buy” rating and set a $66.00 target price on shares of Rapport Therapeutics in a research report on Tuesday, October 20th. Weiss Ratings reissued a “sell (d-)” rating on shares of Rapport Therapeutics in a research note on Thursday, October 15th. Wall Street Zen lowered Rapport Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, August 8th. Finally, Guggenheim lifted their price target on Rapport Therapeutics from $65.00 to $70.00 and gave the company a “buy” rating in a report on Tuesday, October 20th. Two research analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Rapport Therapeutics has an average rating of “Buy” and an average target price of $68.36.

Rapport Therapeutics Company Profile

Rapport Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing precision medicines for central nervous system disorders. The company’s approach is designed to selectively target receptor-associated proteins that regulate synaptic receptors, with the goal of improving therapeutic selectivity and reducing the side effects associated with broader-acting neurological medicines.

Rapport’s lead product candidate, RAP-219, is an orally administered small molecule being developed for neurological conditions, including focal epilepsy.